摘要:
The invention relates mainly to a polymer comprising a hydrocarbon-based main chain bearing carboxylic groups and polyalkoxylated chains and up to 4% by weight of anti-oxidant groups, relative to the weight of the final polymer, grafted to the main chain. It also relates to a method for preparing such a polymer and to an admixture which is of use as a plasticizer of suspensions of mineral particles comprising same. Finally, it is related to the use of such a polymer for fluidifying suspensions of mineral particles and reducing the water demand of hydraulic compositions.
摘要:
The invention relates mainly to a polymer comprising a hydrocarbon-based main chain bearing carboxylic groups and polyalkoxylated chains and up to 4% by weight of anti-oxidant groups, relative to the weight of the final polymer, grafted to the main chain. It also relates to a method for preparing such a polymer and to an admixture which is of use as a plasticizer of suspensions of mineral particles comprising same. Finally, it is related to the use of such a polymer for fluidifying suspensions of mineral particles and reducing the water demand of hydraulic compositions.
摘要:
A compound of formula (I), or a pharmaceutically acceptable salt thereof, where R1 is a (C1-C6)alkyl or (C3-C6)cycloalkyl group; R2 is a (C1-C6)alkyl, (C3-C6)cycloalkyl, (C1-C6)alkenyl, (C1-C6)fluoroalkyl, (C1-C3)fluoroalkoxy, or (C1-C6)alkoxy(C1-C6)alkyl group, substituted: (i) with one to three hydroxyl groups, or (ii) with an NRaRb group, where Ra and Rb are independently a hydrogen atom or a (C1-C3)alkyl group; or a pyrrolidinylmethyl group substituted with one to three hydroxyl groups; R9 is the same as R2 or hydrogen; the R2 and R9 groups independently being substitutable with an —OCOR3 group, where R3 is a natural or unnatural amino acid derivative or a piperidyl group; alternatively, R2 and R9 together form a heterocyclic compound; X and Y are independently a substitutable phenyl or heteroaryl group, the heteroaryl group being a thienyl, pyridyl, pyrimidinyl, thiazolyl, pyrrolyl, or furanyl group; and R6 is a hydrogen or a (C1-C3)alkyl group.
摘要翻译:式(I)化合物或其药学上可接受的盐,其中R 1是(C 1 -C 6)烷基或(C 3 -C 6)环烷基; R2是(C1-C6)烷基,(C3-C6)环烷基,(C1-C6)烯基,(C1-C6)氟烷基,(C1-C3)氟烷氧基或(C1-C6)烷氧基(C1-C6) 烷基,取代:(i)具有一至三个羟基,或(ii)与NR a R b基团,其中R a和R b独立地是氢原子或(C 1 -C 3)烷基; 或被一至三个羟基取代的吡咯烷基甲基; R9与R2或氢相同; R 2和R 9独立地可以被-OCOR 3基团取代,其中R 3是天然或非天然氨基酸衍生物或哌啶基; 或者,R2和R9一起形成杂环化合物; X和Y独立地是可取代的苯基或杂芳基,杂芳基是噻吩基,吡啶基,嘧啶基,噻唑基,吡咯基或呋喃基; R6为氢或(C1-C3)烷基。
摘要:
The present invention relates to compounds of formula (I) wherein R1, R2 and R3 are as defined in the description, to their pharmaceutical compositions and use thereof for the treatment of cancer expressing oncogenic ALK protein, particularly anaplastic large cell lymphoma (ALCL), diffuse large B cell lymphoma (DLBCL), inflammatory myofibroblastic tumors (IMT) and non-small cell lung cancer (NSCLC).
摘要:
A compound of formula (I), or a pharmaceutically acceptable salt thereof, where R1 is a (C1-C6)alkyl or (C3-C6)cycloalkyl group; R2 is a (C1-C6)alkyl, (C3-C6)cycloalkyl, (C1-C6)alkenyl, (C1-C6)fluoroalkyl, (C1-C3)fluoroalkoxy, or (C1-C6)alkoxy(C1-C6)alkyl group, substituted: (i) with one to three hydroxyl groups, or (ii) with an NRaRb group, where Ra and Rb are independently a hydrogen atom or a (C1-C3)alkyl group; or a pyrrolidinylmethyl group substituted with one to three hydroxyl groups; R9 is the same as R2 or hydrogen; the R2 and R9 groups independently being substitutable with an —OCOR3 group, where R3 is a natural or unnatural amino acid derivative or a piperidyl group; alternatively, R2 and R9 together form a heterocyclic compound; X and Y are independently a substitutable phenyl or heteroaryl group, the heteroaryl group being a thienyl, pyridyl, pyrimidinyl, thiazolyl, pyrrolyl, or furanyl group; and R6 is a hydrogen or a (C1-C3)alkyl group.
摘要翻译:式(I)化合物或其药学上可接受的盐,其中R 1是(C 1 -C 6)烷基或(C 3 -C 6)环烷基; R2是(C1-C6)烷基,(C3-C6)环烷基,(C1-C6)烯基,(C1-C6)氟烷基,(C1-C3)氟烷氧基或(C1-C6)烷氧基(C1-C6) 烷基,取代:(i)具有一至三个羟基,或(ii)与NR a R b基团,其中R a和R b独立地是氢原子或(C 1 -C 3)烷基; 或被一至三个羟基取代的吡咯烷基甲基; R9与R2或氢相同; R 2和R 9独立地可以被-OCOR 3基团取代,其中R 3是天然或非天然氨基酸衍生物或哌啶基; 或者,R2和R9一起形成杂环化合物; X和Y独立地是可取代的苯基或杂芳基,杂芳基是噻吩基,吡啶基,嘧啶基,噻唑基,吡咯基或呋喃基; R6为氢或(C1-C3)烷基。
摘要:
The present invention relates to compounds of formula (I) wherein R1, R2 and R3 are as defined in the description, to their pharmaceutical compositions and use thereof for the treatment of cancer expressing oncogenic ALK protein, particularly anaplastic large cell lymphoma (ALCL), diffuse large B cell lymphoma (DLBCL), inflammatory myofibroblastic tumours (IMT) and non-small cell lung cancer (NSCLC).
摘要:
Inhibitors of the oncogenic tyrosine kinase ALK and of the Bcr-Abl mutant T315I Bcr-Abl, pharmaceutical compositions containing the same and their use for the treatment of hyper-proliferative diseases.